Financial Counselors Inc. Trims Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Financial Counselors Inc. reduced its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 7.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,990 shares of the medical equipment provider’s stock after selling 381 shares during the quarter. Financial Counselors Inc.’s holdings in Zimmer Biomet were worth $539,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of ZBH. Ashton Thomas Securities LLC bought a new position in Zimmer Biomet in the 3rd quarter valued at $28,000. Bangor Savings Bank bought a new stake in Zimmer Biomet during the third quarter valued at $31,000. Family Firm Inc. purchased a new position in Zimmer Biomet during the second quarter worth about $33,000. Brooklyn Investment Group bought a new position in Zimmer Biomet in the 3rd quarter worth about $35,000. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new stake in shares of Zimmer Biomet in the 2nd quarter valued at about $43,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Shares of ZBH stock opened at $112.10 on Friday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $101.47 and a fifty-two week high of $133.90. The firm has a market cap of $22.32 billion, a P/E ratio of 21.31, a P/E/G ratio of 2.06 and a beta of 1.02. The business’s 50 day moving average price is $107.29 and its 200-day moving average price is $109.38.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The business had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.80 billion. During the same period in the previous year, the firm earned $1.65 EPS. The company’s quarterly revenue was up 4.1% compared to the same quarter last year. On average, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. JPMorgan Chase & Co. cut their price objective on Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating for the company in a report on Monday, September 16th. BTIG Research decreased their price target on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating on the stock in a report on Thursday, October 3rd. Wolfe Research initiated coverage on shares of Zimmer Biomet in a report on Tuesday, September 10th. They set a “peer perform” rating for the company. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research note on Thursday, October 31st. Finally, TD Cowen dropped their price target on Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating for the company in a research note on Friday, September 6th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, Zimmer Biomet currently has a consensus rating of “Hold” and an average target price of $123.22.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.